Supplement Figure 2. Kaplan–Meier curve of progression-free survival, cause-specific survival, and overall survival in all mRCC patients treated with axitinib or sunitinib as the first-line treatment.

**Progression-Free Survival**

- **Axitinib**: 133, 36, 7, 4, 1, 0, 0
- **Sunitinib**: 270, 57, 13, 4, 1, 1, 0

Probability of survival over time with:
- **P = 0.007**

**Cause-Specific Survival**

- **Axitinib**: 134, 48, 10, 0, 0, 0
- **Sunitinib**: 273, 86, 17, 6, 2, 0

Probability of survival over time with:
- **P = 0.201**

**Overall Survival**

- **Axitinib**: 134, 48, 10, 0, 0, 0
- **Sunitinib**: 273, 86, 17, 6, 2, 0

Probability of survival over time with:
- **P = 0.228**

**HR**

- Axitinib: HR 0.83, 95% CI 0.73–0.95, P = 0.007
- Sunitinib: HR 0.91, 95% CI 0.79–1.05, P = 0.201
- Overall Survival: HR 0.92, 95% CI 0.80–1.05, P = 0.228